ICVAX therapeutic DNA vaccine for people living with HIV in Hong Kong

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 randomized trial compares three delivery methods (TERESA-EPT I, PharmaJet Tropis, and TriGrid electroporation) for the ICVAX therapeutic DNA vaccine in adults with HIV on stable ART. Participants receive four injections at 4-week intervals and are monitored for immune responses through Day 168 and for safety through Day 336. The primary endpoints are safety and antigen-specific T-cell responses; enrollment targets adults aged 18–60 who meet viral load, CD4, and BMI criteria. The trial is conducted at the Chinese University of Hong Kong Phase 1 Clinical Trial Centre with oversight from local collaborators and the sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Tested positive for HIV-1 antibody;
2. Aged 18-60, both male and female;
3. BMI (body mass index) in between 18.5 and 24.9 kg/m2 (including upper and lower limits);
4. Received ART for ≥12 months; no drug resistance occurred during this treatment period;
5. Had \<50 copies/ml of plasma HIV RNA for at least (≥) 12 months prior to screening visit;
6. Had ≥350 cells/μL of CD4+ T cells in the past 6 months and \>200 cells/μL of CD4+ T cells before initiation of ART;
7. Adopted contraception method approved by the investigator from screening period until the end of study;
8. Understand the study and voluntarily sign the ICF.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding or those who plan to give birth in coming two years (including the subject and his/her spouse);
2. ART has been suspended for more than 2 weeks continuously since ART initiation;
3. Participated in other clinical trials within 24 weeks before the screening visit;
4. Has any opportunistic infections or opportunistic tumors that require systemic treatment within 30 days before being recruited; Has any medical events that the investigator believes will affect the safety and immunogenicity evaluation of the drug;
5. Has a history of autoimmune diseases; Has hypersensitivity to the components of this drug including ICVAX recombinant plasmid, NaCl, Na2HPO4 and NaH2PO4·H2O, and shows severe allergies, such as dyspnea, edema and other symptoms after administration;
6. Received approved vaccines within the past 3 months;
7. Received any blood products, immunoglobulin products, or immunosuppressants within 12 weeks before being recruited;
8. Used interferon, systemic corticosteroids, or other immunosuppressants within the last 3 months (except local application);
9. Positive Hepatitis B surface antigen (HBsAg) within 12 months, or positive Hepatitis C virus antibody (HCV Ab) at screening with confirmatory HCV RNA positive;
10. Has any abnormal laboratory results including: neutrophil \<1×109/L, serum creatinine \> ULN, ALT or AST \>1.5×ULN, hemoglobin \< 11g/dL;
11. Has any medical history or clinical manifestations of any physical or mental illness that may affect the subject's completion of this study;
12. Sensitive to electrical pulse stimulation, such as those who are implanted with pacemaker/ Automatic Implantable Cardioverter Defibrillator (AICD), or those who have wearable medical electronic devices including electrocardiogram;
13. Needle phobia;
14. Have contraindications for intramuscular administration such as confirmed thrombocytopenia, any coagulation dysfunction or currently receiving anticoagulation therapy;
15. The investigator considers that he/she is not suitable to participate in this trial.

Where it's running

• The Chinese University of Hong Kong Phase 1 Clinical Trial Centre at Prince of Wales Hospital
  Shatin, New Territories, Hong Kong Recruiting

Study contacts

• Principal investigator: Grace Chung Yan Lui, Dr. — Chinese University of Hong Kong
• Study coordinator: Grace Chung Yan Lui, Dr.
• Email: gracelui@cuhk.edu.hk
• Phone: (852) 5569 9539

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding lenacapavir to ART to try to shrink hidden HIV reservoirs

  This study will test whether giving lenacapavir in addition to a stable ART regimen can reduce hidden HIV reservoirs in adults who have had undetectable viral loads for at least three years.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06819176

• SUSTAIN 2: Sustained HIV treatment support after interruptions in care

  This trial will test whether a six-month adherence club model with multi-month ART dispensing and peer support helps adults with HIV who missed care or have a raised viral load stay on treatment and reach viral suppression over 24 months.

  Recruiting Brigham and Women's Hospital · Cape Town · NCT06554223

• Long-acting injectable treatment for HIV in Belgium

  This study is looking to see how well people with HIV feel about and respond to a long-acting injectable treatment they’ve received.

  Recruiting Belgian Research on AIDS and HIV Consortium · Brussels · NCT06424964

• Universal Test and Connect for HIV services in Cape Town emergency departments

  This project tests whether offering universal HIV testing and connection-to-care in two Cape Town emergency departments can find people with HIV or at high risk and link them to treatment or PrEP.

  Recruiting Johns Hopkins University · Cape Town, Western Cape · NCT06408142

• Evaluating a new HIV vaccine combination in healthy adults

  This study is testing a new combination of HIV vaccines in healthy adults to see if they are safe and can help the body build protection against the virus.

  Recruiting Phase 1 U.S. Army Medical Research and Development Command · Kampala · NCT06205056

• Exploring the effects of gut microbiota on inflammation in people with HIV and alcohol use disorder

  This study tests whether taking prebiotics can help reduce inflammation and improve gut health in people with HIV who also struggle with alcohol use disorder.

  Recruiting Rush University Medical Center · Chicago, Illinois · NCT06139224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.